Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
Thursday, November 2, 2023 1 min read
Key Takeaway: Praxis Precision Medicines, a clinical-stage biopharmaceutical firm, will be part of a panel at the Truist Securities BioPharma Symposium on November 8, 2023. The panel discusses high unmet needs in CNS disorders, reflecting the company's focus on significant healthcare challenges. This event will also be available via live webcast for those unable to attend in person, enhancing its reach and impact.
Market Sentiment Analysis
POSITIVE FACTORS
Praxis Precision Medicines is actively engaging in industry discussions, showcasing its commitment to addressing CNS disorders.
Their participation in a prominent bio-pharma symposium highlights the company's growing influence in the field.
The live webcast format allows for broader accessibility to their valuable insights.
Full Press Release Details
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a panel discussion titled “CNS Companies Looking To Address High Unmet High Prevalence and High Value Diseases” at the Truist Securities BioPharma Symposium on November 8, 2023.
The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 30 days following the event.
Contact Data
Contact
With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Frequently Asked Questions
What panel will Praxis participate in on November 8, 2023?
Praxis will join a panel on addressing high unmet needs in CNS diseases.
Where can I watch the panel discussion live?
The event will be available as a live webcast on Praxis' Investors + Media page.
Will the panel discussion be available for later viewing?
Yes, a replay will be accessible on Praxis' website for 30 days post-event.
What type of therapies is Praxis developing?
Praxis develops therapies for CNS disorders related to neuronal excitation-inhibition.
Who is hosting the BioPharma Symposium?
The Truist Securities BioPharma Symposium will host the panel discussion.